Status:
COMPLETED
Sentinel Lymph Node (SLN) Biopsy for Conjunctival/Eyelid Melanoma
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Eye Disease
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The goal of this clinical research study is to find the sentinel lymph node (SLN) (s) and biopsy it (them) to see if the patient has small or low volume metastatic disease that would otherwise have be...
Detailed Description
You have had your conjunctival or eyelid tumor surgically removed or it is scheduled to have it removed. You will have lymphatic mapping before the tumor is removed. Lymphatic mapping is when a small ...
Eligibility Criteria
Inclusion
- Participants must be 18 years of age or older.
- Histologically documented malignant melanoma of the conjunctiva/eyelid greater than or equal to 1 millimeter in thickness, or those less than 1 mm thick that have evidence of ulceration, mitotic figures or are Clark IV.
- A CXR, liver enzymes, and a head and neck computed tomography (CT) or magnetic resonance imaging (MRI) negative for evidence of metastasis.
- Participant must have a negative ultrasound of regional lymph nodes (i.e., within 6 weeks of study enrollment).
- Patient provided written informed consent. In the event that non-English speaking participants are eligible for this study, a short form (if applicable) or an ICD in their language, will be utilized and completed in accordance with the MDACC Policy for Consenting Non-English Speaking Participants.
Exclusion
- 1\) Pregnant or nursing females.
Key Trial Info
Start Date :
May 30 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 28 2023
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00386906
Start Date
May 30 2000
End Date
September 28 2023
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030